Αρχική World News EMA Recommends Granting a Marketing Authorisation for Camizestrant World News EMA Recommends Granting a Marketing Authorisation for Camizestrant Από Ogkologos - 5 Ιουνίου, 2026 290 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results... 27 Μαρτίου, 2023 Prising open the trap: Getting to grips with targeted cancer drug... 10 Ιανουαρίου, 2022 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... 5 Οκτωβρίου, 2021 Program Connects Adolescents and Young Adults to Quality Cancer Care 24 Οκτωβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Cancer in My Community: Encouraging Cancer Screening in Estonia Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer Population-based lung cancer screening can reduce mortality in people who have... “Your Stories” Podcast: Amplifying Patient Voices